[CAS NO. 3432-99-3] Folitixorin
PRODUCTS SPECIFICATIONS [3432-99-3]
DESCRIPTION [3432-99-3]
Overview
| MDL | MFCD19443704 |
|---|---|
| Molecular Weight | 457.44 |
| Molecular Formula | C20H23N7O6 |
| SMILES | O=C1C2=C(NCC3N2CN(C4=CC=C(C(N[C@]([H])(C(O)=O)CCC(O)=O)=O)C=C4)C3)NC(N)=N1 |
Summary
In Vitro
5,10-methylenetetrahydrofolate reductase (MTHFR) catalyzes the conversion of 5,10-methylenetetrahydrofolate into 5-methyltetrahy-drofolate, which is the major circulating form of folate [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
A colon adenocarcinoma cell suspension is inoculated intrahepatically in a rodent experimental model. Intravenous 5-FU (30 mg/kg) in combination with Folitixorin (15 mg/kg or 30 mg/kg) is administered after 1, 2, 3, 4 and 7 days. 5-FU in combination with Folitixorin (regardless of folate-dose) eliminats tumor take [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Shipping with dry ice.
Storage
-80°C, protect from light, stored under nitrogen
Solvent & Solubility
H 2 O : 5 mg/mL ( 10.93 mM ; ultrasonic and warming and heat to 60°C)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.1861 mL | 10.9304 mL | 21.8608 mL |
| 5 mM | 0.4372 mL | 2.1861 mL | 4.3722 mL |
| 10 mM | 0.2186 mL | 1.0930 mL | 2.1861 mL |
References
- [1] Costantini CL, et al. Resection of hepatic metastasis after 5-fluorouracil and cofactor for colon cancer. Hepatogastroenterology. 2009;56(91-92):645-649.
- [2] Carlsson G, et al. 5-fluorouracil (5-FU) and 5,10-methylene tetrahydrofolate (5,10-CH2FH4) as adjuvant therapy in an experimental rodent colon carcinoma model. Anticancer Res. 1997;17(5A):3671-3674.
- [3] Botto LD, et al. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol. 2000;151(9):862-877.
Synonyms
